PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines

Olaparib for the treatment of breast cancer

(2017) Marie Robert et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current and emerging therapies of HER2-positive metastatic breast cancer

(2016) Abraham Hernández-Blanquisett et al.   BREAST

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models

(2016) L. Oplustil O'Connor et al.   CANCER RESEARCH

Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

(2016) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer

(2016) Cristiano Ferrario et al.   PLoS One

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells

(2015) BANU ARUN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Deoxypodophyllotoxin Induces G2/M Cell Cycle Arrest and Apoptosis in SGC-7901 Cells and Inhibits Tumor Growth in Vivo

(2015) Yu-Rong Wang et al.   MOLECULES

Parp3 Negatively Regulates Immunoglobulin Class Switch Recombination

(2015) Isabelle Robert et al.   PLoS Genetics

Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity

(2014) Tamara Fernández-Marcelo et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

An update on PARP inhibitors—moving to the adjuvant setting

(2014) Amir Sonnenblick et al.   Nature Reviews Clinical Oncology

PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways

(2014) Carole Beck et al.   NUCLEIC ACIDS RESEARCH

PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1

(2014) Marie-France Langelier et al.   NUCLEIC ACIDS RESEARCH

PARP Inhibitor with Selectivity Toward ADP-Ribosyltransferase ARTD3/PARP3

(2013) Anders E. G. Lindgren et al.   ACS Chemical Biology

A Systematic Review of Vinorelbine for the Treatment of Breast Cancer

(2013) Ying-Chun Xu et al.   Breast Journal

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

(2013) Nigel Bundred et al.   INVESTIGATIONAL NEW DRUGS

Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond

(2013) David Davidson et al.   Frontiers in Pharmacology

Tubulin-based Structure-affinity Relationships for Antimitotic Vinca Alkaloids

(2012) Claire Coderch et al.   Anti-Cancer Agents in Medicinal Chemistry

Vinca alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1 downregulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells

(2012) Wei-Hsin Chiu et al.   BIOCHEMICAL PHARMACOLOGY

The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art

(2012) Mike De Vos et al.   BIOCHEMICAL PHARMACOLOGY

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines

(2012) David Davidson et al.   INVESTIGATIONAL NEW DRUGS

The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively

(2012) Daniel M. Klotz et al.   JOURNAL OF CELL SCIENCE

PARP-3, a DNA-dependent PARP with emerging roles in double-strand break repair and mitotic progression

(2011) Christian Boehler et al.   CELL CYCLE

Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells

(2011) David Davidson et al.   INVESTIGATIONAL NEW DRUGS

Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells

(2011) David Davidson et al.   INVESTIGATIONAL NEW DRUGS

Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy

(2011) Lilian Amrein et al.   LEUKEMIA RESEARCH

Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft

(2011) J. M. Senra et al.   MOLECULAR CANCER THERAPEUTICS

PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining

(2011) Stuart L. Rulten et al.   MOLECULAR CELL

Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression

(2011) C. Boehler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PARP inhibitors: its role in treatment of cancer

(2011) Alice Chen   Chinese Journal of Cancer

Synthetic lethality: General principles, utility and detection using genetic screens in human cells

(2010) Sebastian M.B. Nijman   FEBS LETTERS

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

PARP inhibition in BRCA-mutated breast and ovarian cancers

(2010) Stephen L Chan et al.   LANCET

The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets

(2010) Raga Krishnakumar et al.   MOLECULAR CELL

Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer

(2008) Thomas D. Penning et al.   JOURNAL OF MEDICINAL CHEMISTRY